Figure 3 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer

Le résumé fourni par la source

In vitro and in vivo characterization of KLK2 × CD3 in preclinical models. A and B, Binding of KLK2 × CD3 to (A) VCaP (KLK2+) and (B) DU145 (KLK2−) cells. A representative dose–response binding curve is shown; n = 5. C–F, Evaluation of KLK2 × CD3 on (C) T cell–mediated cytotoxicity, (D) T-cell activation, and (E and F) TNF-α and IFN-γ cytokine release in vitro, in PBMC from five healthy donors. Mean values ± SEM are shown. n = 5. G, T cell–engrafted NSG mice bearing established VCaP tumors were intraperitoneally dosed with KLK2 × CD3 at 0.2 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg, and 15 mg/kg, compared with control (eight total doses). Tumor volume was measured twice weekly, and the results are presented as the mean tumor volume ± SEM for each group (n = 8 per group).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.